Vaxart (NASDAQ: VXRT) is gearing up for a potential roll-out of its experimental COVID-19 vaccine.
The clinical-stage biotechnology company is expanding its partnership with Kindred Biosciences (NASDAQ: KIN) to manufacture its oral vaccine candidate for the novel coronavirus. Under the terms of the deal, Kindred's plants will produce bioreactors for Vaxart's clinical trials.
Vaxart and Kindred Biosciences are teaming up to advance their COVID-19 vaccine production capabilities. Image source: Getty Images.
For further details see:
Vaxart Ramps Up Coronavirus Vaccine Production